Clinigen Group plc Director/PDMR Shareholding (8570S)
October 05 2017 - 9:18AM
UK Regulatory
TIDMCLIN
RNS Number : 8570S
Clinigen Group plc
05 October 2017
5 October 2017
PDMR Share Dealings
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Company'), the
global pharmaceutical and services group, announces that it was
notified on 5 October 2017 that the following transactions took
place.
Steve Glass, Chief Commercial Officer, has exercised a total of
32,858 nil cost options over ordinary shares of 0.1 pence each in
the Company. The options have been satisfied by shares from the
Clinigen Group Employment Benefit Trust. He has subsequently sold
15,498 ordinary shares of 0.1 pence each in the Company at a price
of 1147 pence per share in order to meet the expected tax
obligations.
Following these transactions, Mr Glass's total beneficial
interest in the Company is 17,360 ordinary shares representing
approximately 0.02 per cent of the current issued share
capital.
Separately, Debbie Ainge, Chief Operating Officer, has exercised
a total of 9,471 nil cost options over ordinary shares of 0.1 pence
each in the Company. The options have been satisfied by shares from
the Clinigen Group Employment Benefit Trust. She has subsequently
sold 9,471 ordinary shares of 0.1 pence each in the Company at a
price of 1150 pence per share.
Following these transactions, Mrs Ainge's total beneficial
interest in the Company is 10,254 ordinary shares representing
approximately 0.01 per cent of the current issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging
managerial responsibilities/person
closely associated
---- ---------------------------------------------------------------
a) Name Steve Glass
---- ---------------------- ---------------------------------------
2 Reason for the notification
---- ---------------------------------------------------------------
a) Position/status Chief Commercial Officer
/ PDMR
---- ---------------------- ---------------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ---------------------- ---------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- ---------------------------------------------------------------
a) Name Clinigen Group plc
---- ---------------------- ---------------------------------------
b) Legal Entity N/A
Identifier
---- ---------------------- ---------------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type
of instrument; (ii) each type of
transaction; (iii) each date; and
(iv) each place where transactions
have been conducted
---- ---------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence
of the financial each
instrument, GB00B89J2419
type of
instrument
Identification
code
---- ---------------------- ---------------------------------------
b) Nature of 1. The exercise of 32,858
the transaction options over ordinary shares
in the Company following
the vesting of an award
granted under the Long Term
Incentive Plan.
2. The sale of 15,498 ordinary
shares in the Company made
in order to meet expected
tax obligations arising
from the transaction described
in 1.
---- ---------------------- ---------------------------------------
c) Currency GBP
---- ---------------------- ---------------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ---------------------- ------------------ -------------------
1147p 15,498
--------------------------- ------------------ -------------------
e) Aggregated 15,498
information
- Aggregated 1147p
volume
- Price GBP177,762
- Aggregated
total
--------------------------- ---------------------------------------
f) Date of 4 October 2017
the transaction
---- ---------------------- ---------------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ---------------------- ---------------------------------------
1 Details of the person discharging
managerial responsibilities/person
closely associated
---- --------------------------------------------------------------
a) Name Debbie Ainge
---- ---------------------- --------------------------------------
2 Reason for the notification
---- --------------------------------------------------------------
a) Position/status Chief Operating Officer
/ PDMR
---- ---------------------- --------------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ---------------------- --------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- --------------------------------------------------------------
a) Name Clinigen Group plc
---- ---------------------- --------------------------------------
b) Legal Entity N/A
Identifier
---- ---------------------- --------------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type
of instrument; (ii) each type of
transaction; (iii) each date; and
(iv) each place where transactions
have been conducted
---- --------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence
of the financial each
instrument, GB00B89J2419
type of
instrument
Identification
code
---- ---------------------- --------------------------------------
b) Nature of 1. The exercise of 9,471
the transaction options over ordinary shares
in the Company following
the vesting of an award
granted under the Long Term
Incentive Plan.
2. The sale of 9,471 ordinary
shares in the Company.
---- ---------------------- --------------------------------------
c) Currency GBP
---- ---------------------- --------------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ---------------------- ------------------ ------------------
1150p 9,471
--------------------------- ------------------ ------------------
e) Aggregated 9,471
information
- Aggregated 1157p
volume
- Price GBP108,917
- Aggregated
total
--------------------------- --------------------------------------
f) Date of 4 October 2017
the transaction
---- ---------------------- --------------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ---------------------- --------------------------------------
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283
495 010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief Financial
Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20
Broker 7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners (media Tel: +44 (0) 20
relations) 7457 2020
Melanie Toyne-Sewell / Alex
Shaw Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time through three areas
of global medicine supply; clinical trial, unlicensed and licensed
medicines.
Clinical Trial Services
Clinigen is the global market leader in the specialist supply
and management of quality-assured comparator medicines and services
to clinical trials and Investigator Initiated Trials.
Unlicensed Medicines
Clinigen is the global leader in ethically sourcing and
supplying unlicensed medicines to hospital pharmacists and
physicians for patients with a high unmet medical need. The Group
manages early access programmes to innovative new medicines and
provides 'on-demand' access globally to medicines which remain
unlicensed at the point of care.
Commercial Medicines
The Group acquires global rights to niche hospital-only and
critical care products, revitalising these assets around the world
and returning them back to sustained growth. The Group also
provides access to licensed and branded generic medicines in the
Africa and Asia Pacific region.
For more information on Clinigen, please visit
www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFLSIRLEIID
(END) Dow Jones Newswires
October 05, 2017 10:18 ET (14:18 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Jul 2023 to Jul 2024
